S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME

• Raffaele Badolato,
• Jean Donadieu,
• 4whim Study Group

Affiliations

Raffaele Badolato

1 University of Brescia & ASST Spedali Civili, Department of Clinical and Experimental Sciences, Brescia, Italy

Jean Donadieu

2 CHU Paris Est - Hôpital d’Enfants Armand-Trousseau, Paris, France

4whim Study Group

3 Multiple Institutions, Global including, United States